Platelet Concentrate

ApprovedSmall molecule

Platelet Concentrate is one of 102 small molecule programs targeting Immune Thrombocytopenia. It is currently in Approved.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune ThrombocytopeniaActive, not recruiting

OsteoarthritisActive, not recruiting

CirrhosisActive, not recruiting

Immune ThrombocytopeniaPhase 3

Active, not recruiting

OsteoarthritisPreclinical

Active, not recruiting

CirrhosisApproved

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Platelet Concentrate

SShandong University

Approved

1 2

Ilaris

Novartis

Preclinical

2 3

Toradol

Roche

Preclinical

1 4

Bayer Aspirin

Bayer

Preclinical

—5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 7

Catapres

Boehringer Ingelheim

Preclinical

1 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Paracetamol

GSK

Preclinical

4 10

Benadryl

PParkedale

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Cirrhosis

NCT05667805

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia

Unknown status·SShandong University·Phase 3·NCT03492515·90 enrolled

Cirrhosis1 trial

Coagulation in Cirrhosis

Recruiting·MMedical University of Vienna·Phase 4·NCT05667805·400 enrolled

Osteoarthritis1 trial

Single Blinded First CMC Osteoarthritis Treatment

Recruiting·KKettering Health Network·N/A·NCT03196310·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Platelet Concentrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Platelet Concentrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Platelet Concentrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShandong University

Platelet Concentrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Cirrhosis1 trial

Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News